The disclosure relates to systems and methods for creating a puncture in tissue. More specifically, the disclosure relates to a method and device to create a puncture (or a shunt) from the left atrium (LA) to aorta (Ao) or Ao to LA for communication between LA and Ao or Ao and LA.
It is often necessary to create perforations between various chambers of the heart and surrounding central vasculature to study etiology, pressure gradients, or enable end-therapy. For example, a left ventricular assist device (LVADs) have been widely used to help heart failure (HF) patients provide sufficient blood flow to peripheral organs, keeping patients alive as a bridge to transplantation or engendering return of native heart function. Percutaneous catheter LVAD support through connection of the left atrium (LA) to the aorta (LA-Ao) is used as a bridge to recovery in heart failure patients specifically because it is non-invasive to ventricular muscle. These LVAD catheters are currently track from the LA through the mitral valve to the LV through the aortic valve, to the aorta. Certain limitations may be associated with this conventional method, such as effusions, valve stenosis, hematoma, and vessel dissection.
The following summary is intended to introduce the reader to various aspects of the detailed description, but not to define or delimit any invention.
There is a need to create a direct pathway/communication between the aorta and the left atrium while avoiding the mitral and aortic valves and the left ventricle.
Creating a pathway (communication) percutaneously between LA and Ao is significant as the end-therapy device, approach, and selected tools used to create the pathway play a role in optimal site-selection.
There is a need for a streamlined workflow using a puncture device, for example an atraumatic radio frequency (RF) guidewire, to reduce the number of exchanges and optimizes workflow while reducing complications during creation of a LA-Ao communication (e.g., effusions into pericardial space, vessel dissection, hematoma). The ability of the RF wire to navigate tortuous anatomy, puncture at the selected site through steering, deployment of an atraumatic anchor to support dilation and exchange of large sheath systems removes need for exchanging access devices for multiple devices. For example, the RF wire can function in each step of the procedure as a support guidewire.
Methods for creating a pathway between an aorta and a left atrium of a patient's heart are disclosed. According to some aspects, a method for creating a pathway between an aorta and a left atrium of a patient's heart includes: a. via a femoral venous access site and a right atrium, advancing a puncture assembly device towards an interatrial septum, wherein said puncture assembly device comprises a sheath, a dilator, and a flexible puncturing device; b. positioning a perforating tip of puncturing device adjacent an interatrial septum proximate a left atrium; c. advancing the perforating tip to perforate through the interatrial septum creating a pathway between the right atrium and left atrium; d. advancing the puncturing device to the left atrium; e. advancing the sheath and the dilator over the puncturing device through the septum and into the left atrium such that perforating tip of the puncturing device is aligned with a distal tip of the sheath and a distal tip of the dilator, forming said puncturing assembly; f. positioning the puncturing assembly at a target site within the left atrium to gain access to the aorta; and g. advancing the perforating tip of the puncturing device to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium.
In some examples, the puncturing device is a radiofrequency puncturing device, the perforating tip comprises a radiofrequency perforation electrode, and step g. comprises delivering radiofrequency energy from the radiofrequency perforation electrode while advancing the perforating tip.
In some examples, the method further includes: h. after step g., advancing a dilating tip of the dilator over the perforation device and through the pathway to dilate the pathway between the aorta and the left atrium; and step i. retracting the dilator through the sheath. The sheath can be selected from a steerable sheath, a fixed curve sheath, a small-bore steerable sheath, a large-bore steerable sheath, or a telescoping steerable sheath, and the dilator can be a flexible dilator.
In some examples, the method further includes: j. after step i., delivering a therapeutic device to the pathway via the sheath. Step j. can include positioning a shunt in the pathway or positioning a stent in the pathway.
In some examples, the method may further include: j. via the femoral venous, exchanging the sheath for a large-bore steerable sheath; and i. delivering a therapeutic device to the pathway via a large-bore steerable sheath.
In some examples, the method further includes: h. advancing a snare towards the aorta via an arterial access site (e.g., left or right femoral artery); and i. after step g., snaring the puncturing device with the snare. In some examples, the method further includes: j. after step i., retracting the snare to advance the puncturing device out of the body towards the arterial access site.
In some examples, the method further includes delivering a therapeutic device over the puncturing device towards the pathway, via the arterial access site.
In some examples, at least one of fluoroscopy, angiography, electro-anatomical mapping, intracardiac echocardiography, and transesophageal echocardiography is carried out concurrently with at least one of steps a. to g. In some examples, the method further includes confirming the creation of the pathway with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiography.
According to some aspects, a method for creating a pathway between an aorta and a left atrium of a patient's heart includes: a. via an inferior artery, advancing a perforating tip of a puncturing device towards the aorta; b. positioning the perforating tip adjacent a wall of the aorta, proximate the left atrium; and c. advancing the perforating tip to perforate through the wall of the aorta and then through a wall of the left atrium, to create a pathway between the aorta and the left atrium, wherein the creation of the pathway can be confirmed with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiography.
In some examples, the method further includes: d. via the inferior artery, advancing a dilator over the puncturing device to the aorta; e. after step c., advancing a dilating tip of the dilator over the perforation device and through the pathway to dilate the pathway between the aorta and the left atrium.
In some examples, the dilator can be a steerable dilator or a flexible dilator.
In some examples, the method may further includes: f. via the inferior artery, advancing a sheath over the dilator and the perforation device to the aorta and then to the left atrium; and g. after step e., retracting the dilator through the sheath.
In some examples, the dilator can be a hybrid dilator having features that provide a dual functionality of a sheath and a dilator, and the method may further includes: f. via the inferior artery, advancing the hybrid dilator over the perforation device to the aorta and then to the left atrium. More specifically, the hybrid dilator functions as a single device that removes the need for using conventional sheath/dilator assemblies and eliminates the need for an assembly, resulting in fewer exchanges, and reduced procedure times.
In some examples, the method further includes: d. advancing a snare towards the left atrium via a venous access site, a right atrium and then across an interatrial septum; and e. after step c., snaring the puncturing device with the snare. In some examples, the method further includes: f. after step e., retracting the snare to advance the perforating tip of the puncturing device out of the body towards the venous access site.
In some examples, the method further includes confirming the creation of the pathway between the left atrium and aorta, and/or crossing of the interatrial septum with at least one of fluoroscopy, electro-anatomical mapping (EAM), pressure differentials between the aorta and left atrium, contrast injection, or using intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE).
The accompanying drawings are for illustrating examples of articles, methods, and apparatuses of the present disclosure and are not intended to be limiting. In the drawings:
Various apparatuses or processes or compositions will be described below to provide an example of an embodiment of the claimed subject matter. No example described below limits any claim and any claim may cover processes or apparatuses or compositions that differ from those described below. The claims are not limited to apparatuses or processes or compositions having all the features of any one apparatus or process or composition described below or to features common to multiple or all of the apparatuses or processes or compositions described below. It is possible that an apparatus or process or composition described below is not an embodiment of any exclusive right granted by issuance of this patent application. Any subject matter described below and for which an exclusive right is not granted by issuance of this patent application may be the subject matter of another protective instrument, for example, a continuing patent application, and the applicants, inventors or owners do not intend to abandon, disclaim or dedicate to the public any such subject matter by its disclosure in this document.
Generally disclosed herein are methods for carrying out cardiac procedures, and more specifically, cardiac procedures in which a pathway (also referred to as a “communication”) is created between the aorta (e.g., the ascending aorta) and the left atrium (LA) of a patient. Such procedures can be carried out, for example, to allow for the insertion of a therapeutic device (e.g., a shunt or a stent) into the pathway, to treat heart defects.
In accordance with some embodiments of the present invention, some details of the devices are disclosed in application number PCT/IB2013/060287 (now publication number WO2015019132), and in application number PCT/IB2017/056777 (now publication number WO2018083599), which are incorporated herein by reference in its entirety.
In one broad aspect, embodiments of the present disclosure provides a method and device to create a communication or pathway from the left atrium (LA) to aorta (Ao) comprising, via a femoral venous access site, advancing a perforating tip of a puncture assembly towards the right atrium, accessing the left atrium via the septum and advancing the perforating tip to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium. The puncture assembly may include a sheath, a dilator, and a puncturing device usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The puncturing device is atraumatic and may include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions. For example, the puncturing device is capable of navigating vasculature through the femoral artery or femoral vein (for example when using for transseptal puncture) through to the aorta or LA, respectively.
The sheath (such as steerable sheath, fixed curve sheath, or two telescoping steerable sheaths instead of one for enhanced site-selection, small-bore steerable sheath <10 Fr, or large-bore steerable >15 Fr,) and the dilator are advanced over the guidewire (such as a radio frequency wire (RF wire), flexible/steerable needle, mechanical puncture wire, or bovie mechanical guidewire) to reach the target site, for example the left atrium or the aorta. After crossing the target site, the guidewire (for example, an RF wire) is snared, for example with a lasso catheter. The sheath may then be removed leaving the guide wire (such as an RF wire) within the LA for advancing end-therapy devices over the wire. In some instances, the access sheath may be advanced into the LA if the access sheath can support delivery of end therapy devices. In some cases, the selected end-therapy may not fit in the arterial vasculature chosen. A larger bore pathway to the target site can be created through the puncture to facilitate large-bore access into the LA-Ao and the selected end-therapy can then be tracked over the wire up the femoral artery or femoral vein and through the puncture.
In some embodiments, a vascular snare or lasso catheter is used. The lasso catheter comprise an elongated sheath connected to a handle at the proximal end. One or more loops are connected to the distal-end portion of the lasso catheter. The one or more loops may be opened and closed by manipulating the proximal end. When the one or more loops are open, a device may be ensnared within the loop. Successful ensnarement is usually confirmed through imaging such a fluoroscopy. Once ensnarement is achieved, the device can be retracted by the lasso.
In further instances, the wire may be externalized to support advancement of end-therapy devices. The access site to externalize out may be the femoral artery, common carotids, or femoral vein. With an externalized wire of sufficient length, it can be used to support stiffer end-therapy devices. In some cases, the selected end-therapy may not fit in the arterial vasculature chosen. To facilitate large-bore access into the LA-Ao communication (pathway) made, it can then be tracked over the RF wire up the femoral artery or femoral vein and through the puncture.
Access to the vasculature for creation of the communication (pathway) may be achieved from a femoral approach through the femoral vein or femoral artery. These specific embodiments can also be utilized for other approaches from central vasculature or for the creation of communication between other heart chambers and heart spaces with the intent of facilitating study or placement of end-therapy devices.
As a feature of this aspect, the site of puncture can be determined through several visualization methods, including but not limited to: (1) fluoroscopy through the use of RO (radiopaque) markers on the sheath and RF wire system; (2) electro-anatomical mapping for real-time placement of the RF wire and sheath with targets pre-determined on CT or in real-time (in real-time, the lasso catheter or guidewire with one or more electroanatomical (EAM) markers can be placed in the LA or Ao as a target for positioning and relative orientation; and (3) echogenic markers or features on either the RF wire or the supporting catheter can enable use of ICE or TEE for delineation of etiology and optimal target site to avoid damaging surrounding vasculature. Support and etiology of surrounding vasculature can also be used to interpret site selection. For creating the communication to or from the ascending aorta, for example, locating above the sinotubular junction (STJ) can aid in alignment with the LA. In cases where end-therapy sheaths need to be exchanged for the catheter system over the guidewire, such as an RF wire which is advanced during RF energy application, it can be useful to prevent un-intended dilation with the catheter system. While tenting tissue during site selection, the dilator (preferably sufficiently flexible dilator) can be retracted into the flexible sheath until the dilator and the sheath tip are aligned. As the flexible dilator easily conforms to the shape of the sheath, this can be completed without losing the optimal puncture location selected, resulting in decreased pressure on target tissue from sheath tip.
In some such examples, confirmation of access into Ao from LA or from the LA to Ao can be determined through several methods, including but not limited to: (1) fluoroscopy through the use of RO markers on the sheath and RF wire system; (2) electro-anatomical mapping for real-time placement of the guidewire, for example RF wire, and sheath with targets pre-determined on CT or in real-time (in real-time, a catheter or guidewire with one or more EAM markers can be placed in the LA or Ao as a target for positioning and relative orientation); (3) pressure differentials from the Ao to the LA and vice-versa; (4) contrast injection; and (5) echogenic markers or features on either the coil or the catheter can enable use of ICE or TEE for confirmation of location.
In an embodiment, an assembly is provided for puncturing tissue, where the assembly comprises a puncturing device for puncturing tissue. The puncturing device preferably comprises an atraumatic tip. Preferably, the atraumatic tip comprises an energy delivery device such as an electrode, capable of delivering radiofrequency energy to the target tissue, thereby creating a puncture in the tissue. In some examples, the puncturing device may be flexible, enabling the puncturing device to also be used as an exchange or guidewire. The assembly additionally comprises ancillary devices, such as a sheath and/or dilator, for supporting the flexible puncturing device. The sheath and/or dilator are operable to be selectively usable with the flexible puncturing device. In some examples, the flexible puncturing device is an energy-based device for delivering energy to the tip of the puncturing device in order to puncture the septum. In some embodiments, the flexible puncturing device has a lumen and one or more apertures. The lumen and aperture may combine to form a pressure transmitting lumen. The flexible puncturing device may be operable to be coupled to a pressure sensing mechanism, such as a pressure sensor, to measure the pressure transmitted through the lumen. In some embodiments, fluid (such as imaging or contrast fluid) is injected through the lumen and one or more apertures.
The assembly enables the flexible puncturing device to be usable independently from the ancillary devices as an exchange or guidewire during a portion of the procedure and to be usable in co-operation with other devices for puncturing tissue during another portion of the procedure. This reduces the number of exchanges needed by allowing the flexible puncturing device to be used for puncturing tissue, and as an exchange wire. The ancillary devices facilitate positioning of the energy delivery portion of the puncturing device against the desired target tissue location and may additionally reduce procedure complexity and enhance procedural efficiency.
Referring to
In some examples, the distal portions (sections) 116 of the assembly 104 comprise a pigtail or J-tip configuration, as shown in
In some embodiments of the puncture assembly device 104, the dilator 200 and sheath 300 each defines a respective lumen through which devices may be inserted (as shown in
In some embodiments, the sheath 300 is a steerable sheath. In some embodiments, the steerable sheath is unidirectional, i.e., it allows deflection in a single direction. In other embodiments, a bi-directional sheath may be used. Alternately, in some embodiments, a fixed curve sheath may be utilized in place of an articulating sheath, depending on the tortuosity of the vasculature.
In some examples, the dilator 200 provides stiffness to the puncture assembly device 104 to facilitate force transmission to a distal end of the puncture assembly device 104. In other examples, the sheath 300 may be used with the dilator 200 to provide stiffness to the puncture assembly device 104 to enable force or torque to be transmitted to a distal end of the puncture device 100. In some such examples, the sheath 300 may be coupled to the dilator 200 which enables force and/or torque transmission using one or more of the components (i.e., the sheath 300 or the dilator 200). In other words, the user may just manipulate the sheath 300 or the dilator 200) and the puncture device 100 will follow the guidance and/or direction of the sheath 300 or the dilator 200.
In some embodiments, the dilator 200 is a flexible dilator used with a steerable sheath 300 to access a region of tissue within a patient's body. The steerable sheath 300, defining a lumen therethrough for receiving the dilator, has a range of deflection angles and to achieve a range of curvature upon actuation. The dilator 200 includes a substantially flexible or soft section that provides minimal resistance to deflection and is operable to be deflected under guidance to allow the dilator 200 to reach a desired site within a region of tissue within the patient's body to facilitate advancement of the distal end region. The flexible region allows the dilator 200 to conform to the curvature of the steerable sheath 300 that is achieved through actuation of the steerable sheath. In some embodiments, the distal end of the dilator 200 extends beyond the distal end of the sheath 300 to improve access to the target tissue within the patient's body.
In an embodiment, the dilator 200 is for use with an ancillary device such as a steerable sheath to access a region of tissue or tissue site within a patient's body, the steerable sheath defining a lumen therethrough for receiving the dilator and having a range of deflection angles. The dilator 200 comprises a rigid distal end region; and a flexible intermediate region. The dilator 200 can be configured in a such a way that, when the dilator is inserted into the lumen of the steerable sheath, the location of the flexible intermediate region corresponds to a location of a region of the steerable sheath that is amenable to deflection (also referred to as a “curvature-imparting region” or an “articulating region”). The dilator 200 may further comprise a rigid distal end region having a rigidity greater than the flexible intermediate region to enable the dilator to advance through tissue.
In the aforementioned embodiments, the dilator 200 is structured in such a way that, during use, the flexible intermediate region of the dilator is configured to provide minimal resistance to deflection so as to allow the deflectable region of the steerable sheath to deflect, thereby allowing the steerable sheath to reach a desired deflection angle from said range of deflection angles, to position the dilator rigid distal end region at a desired location within the region of tissue, allowing the dilator rigid distal end region to facilitate advancement of the dilator there-through.
In the embodiments, the dilator 200 described above are sufficiently flexible to allow the ancillary device to guide and position the dilator and/or additional devices in a wide array of patient anatomies. Embodiments of the dilator 200 accomplish this function by providing a flexible intermediate region having reduced stiffness. The location of the flexible region, when the dilator is inserted into/through the ancillary device, corresponds to a region of the ancillary device that is amenable to deflection or has a particular shape or curve, whereby the flexibility of the dilator at that location helps to ensure that the dilator does not substantially impair the ability of the ancillary device to retain, maintain or reach its intended shape or curvature. In some embodiments, the dilator 200, while being sufficiently flexible along the intermediate region, has sufficient stiffness along a distal end region to allow the dilator to be tracked or advanced across tissue for dilating a perforation or puncture at the desired target tissue site.
In accordance with another embodiment, as shown in
Additionally, the elongate member 204 of the dilator 200 further comprises a distal end region 206 that is formed distally adjacent to the flexible intermediate region 208, such that the flexible intermediate region 208 continues distally until (and terminates at) a proximal boundary or edge of the distal end region 206. In other words, the distal end region 206 extends proximally from the distal edge of the dilator 200 until a distal edge of the flexible intermediate region 208. The distal end region 206 has a stiffness or rigidity that is greater than the flexible intermediate region 208 to facilitate advancement of the dilator 200 through the tissue once the dilator 200 has been positioned at the desired tissue site, such as a desired puncture site. The stiff or substantially rigid distal end region 206 provides enhanced pushability and may prevent deformation thereof during advancement of the distal end region 206 through the tissue, for example at the puncture site to dilate the puncture site.
As outlined previously, the dilator 200 is usable with a steerable sheath 300 to access a region of tissue within a patient's body. The steerable sheath 300 may be of the type shown in
In a specific embodiment, an 8.5 French steerable sheath 300 with a 72 cm usable length and an 8.5 French dilator 200 with a usable length of 95 cm can be used. The dilator 200 tapers down to an outer diameter (OD) of about 0.046″ (about 1.2 mm) and an inner diameter (ID) of about 0.036″ (about 0.9 mm) at the distal tip.
In one embodiment, with reference to
With reference now to
In one specific example, with reference now to
In one embodiment, the dilator 200 is usable with an ancillary device such that it allows the ancillary device to maintain or reach its intended shape or curvature in order to access a desired tissue site within a region of tissue within a patient's body. The dilator 200 may be of the type described herein above, that comprises a rigid distal end region 206 and a flexible intermediate region 208 terminating at the distal end region 206, with the rigid distal end region 206 having a rigidity greater than the flexible intermediate region 208 to enable the dilator 200 to advance through tissue. The dilator 200 is configured for use in conjunction with the ancillary device such that during use, the flexible intermediate region 208 corresponds to a region of the ancillary device that is functional for imparting or providing a curvature. In one particular example, the dilator 200 is advanced over or through the ancillary device such that such that during use the flexible intermediate region 208 of the dilator 200 does not affect the region of the ancillary device that is functional for imparting a curvature, allowing the ancillary device to substantially maintain or reach its intended position or shape in order to position the dilator rigid distal end region 206 at a desired location within the region of tissue.
In one such example, the ancillary device comprises a steerable device such as a sheath, catheter or guidewire that is steerable, where the ancillary device is functional for imparting a curvature by actuation of the ancillary device. When in use in conjunction with the dilator 200, the flexible intermediate region 208 of the dilator does not inhibit or prevent the ancillary device from reaching its intended curvature upon actuation to position the dilator distal end region 206 at a desired location. In another example, the ancillary device comprises a telescoping steerable sheath to enhance target site-selection.
Alternatively, in some embodiments, the ancillary device comprises a fixed curve device such as a fixed curve sheath that has a preformed curve. Similar to embodiments discussed previously herein, the fixed curve sheath is usable with the dilator 200 and during use the flexible intermediate region 208 of the dilator 200 does not affect the preformed curvature of the sheath, thus allowing the sheath to position the rigid distal end 206 of the dilator 200 at the desired location within the region of tissue. Furthermore, the use of the dilator 200, in accordance with an embodiment of the present invention, may prevent the need for over curving the sheath in anticipation of a substantial decrease in curvature of the sheath once the dilator 200 there-through.
In some embodiments, it may be desirable to use a hybrid dilator comprising features that provide a dual functionality of a sheath and a dilator. The hybrid dilator provides the smoothness of a standard dilator with the control of a steerable sheath. More specifically, the hybrid dilator functions as a single device that removes the need for using conventional sheath/dilator assemblies and eliminates the need for an assembly, resulting in less waste, fewer exchanges, and reduced procedure times. The hybrid dilator may comprise a sheath-like handle with familiar torque and tactile control. For example, the hybrid dilator comprises a proximal portion of a sheath hub with an actuation mechanism to steer the distal portion. The shaft extending from the hub is similar to that of a dilator wherein the distal tip comprises a tapered portion which may be used to dilate the puncture.
As outlined above, in some embodiments described herein above, the dilator 200 comprises varying regions of flexibility (i.e., rigid and flexible regions) to define a hybrid medical device. Since the dilator 200 comprises a substantially constant OD and ID and thus substantially constant wall thickness along its length, the behavior of the various regions, in terms of rigidity, is governed by the stiffness of the materials used. For example, the higher the stiffness of a material, the greater the rigidity, and the lower the stiffness of the material the lower the rigidity. Alternatively, in other embodiments, a single material may be used to form the dilator where the varying regions of flexibility are provided by varying the wall thickness along the respective regions. For example, an HDPE dilator may be provided with a relatively thin wall thickness along the flexible intermediate region and a relatively thicker wall thickness along the distal end region, in order to provide a dilator with the functionality described previously hereinabove.
In accordance with embodiments of the present invention, as described hereinabove,
Creating Pathway (Communication) Between the Left Atrium and Aorta via Inferior Approach
Access to the vasculature for creation of the pathway is achieved from inferior approach through the right atrium and then the interatrial septum. The vasculature may be accessed using traditional access procedures, such as the Seldinger technique, with the placement of a hemostatic valve (known and used in medical procedures requiring the insertion of a catheter into the vascular system of a patient). A puncturing device 100 may then be introduced into the patient's vasculature and then to the right atrium which would provide the most direct path to the first target puncture site of the interatrial septum. In the following embodiments, the puncturing device 100 is illustrated as a flexible puncturing device 100, such as a flexible puncturing guidewire; however, the puncturing device may be any alternative device used for puncturing tissue, such as a steerable needle, a steerable power catheter or a mechanical puncturing wire.
Referring now to
In some examples of this method,
Referring to
Referring to
With the flexible puncturing device 100 situated within the left atrium 512, the dilator 200 and the sheath 300 are advanced along flexible puncturing device 100 into the left atrium 512 until the distal tip of the flexible puncturing device 100 is aligned with the distal tip of the dilator 200, as shown in
In some examples, the target site of the transseptal perforation, advancement of the of puncturing device 100 from right atrium to left atrium, and the position of the perforating tip 112 of puncturing device 100 can be confirmed using fluoroscopy (e.g. in examples wherein the puncturing device 100 or the assembly 104 includes one or more radiopaque markers or features), angiography, electro-anatomical mapping (EAM) (e.g. to confirm real-time positioning of the perforating tip 112 using real-time or pre-determined computerized tomography data, in conjunction with the assembly 104 or guidewire with one or more EAM markers in the right atrium 704), intracardiac and/or transesophageal echocardiography (ICE and/or TEE) (e.g. using echogenic markers or features on the puncturing device 100).
Referring to
Referring to
Once the assembly 104 is directed at the target puncturing site (as in
Referring to
Referring to
Alternatively, the sheath 300 can be retracted towards femoral vein (for example, inferior vena cava 706) and a secondary sheath (e.g., a large bore sheath designed for therapeutic device delivery) can be advanced via the femoral vein. The secondary sheath can then be used to deliver a therapeutic device to the pathway.
In some embodiments, the flexible wire may be externalized to support advancement of end-therapy devices through the perforation between the aorta and the left atrium. Externalization of the flexible puncturing device 100 may be achieved through, for example, the patient's femoral artery or femoral vein. An externalized flexible wire having sufficient length may be used to support the introduction and positioning of stiffer therapeutic devices, such as end-therapy devices or end-therapy delivery devices. In this embodiment, the puncture device 100 would be dimensioned such that while the device is still accessible from the inferior entry point (for example, inferior vena cava 706) it is also externalized via the arterial access (e.g., left or right femoral artery). By allowing both ends of the puncture device 100 to be simultaneously secured by the user, the puncture device may act as a stiff support track allowing advancement of end-therapy devices through the femoral access.
In another embodiment, a method for creating a perforation from the aorta to the left atrium is illustrated in
In accordance with a method aspect of this disclosure for creating a perforation from the aorta to the left atrium, the assembly 104 of the sheath 300, dilator 200, and flexible puncturing device 100 are advanced into the ascending aorta 504, as shown in
Referring to
Once the position of the target is confirmed, radiofrequency energy can then be applied to the flexible puncturing device 100 and delivered to the tissue via the energy delivery device 114 to create the perforation. The flexible puncturing device 100 is advanced during energy application, creating a puncture between the aorta and left atrium, forming a pathway for fluid communication between the aorta and the left atrium. In an alternative embodiment, the puncturing device 100 may comprise a sharp distal tip which may be used to mechanically puncture the tissue. Confirmation of target site and access into the left atrium from the aorta may be achieved through various methods described above, including fluoroscopy, electro-anatomical mapping (EAM), pressure differentials between the aorta and left atrium, contrast injection, or using intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE).
Referring to
Referring to
Referring to
The present disclosure in various embodiments thus provides a system and method for the creation of a pathway or communication (including for example a perforation an atrial septum and perforation between an aorta and a left atrium). Visualization techniques as disclosed herein are advantageous for positioning the assembly 104 (puncturing device 100, dilator 200, sheath 300 and/or lasso catheter 600) within a patient's heart and for confirming that the desired ancillary device has entered into the aorta, the left atrium or right atrium subsequent to perforation or puncture. It should be noted, however, that a method of the present disclosure may be practised without any or all of pressure monitoring or visualization and is thus intended to comprise a method of creating a perforation/crossing in a tissue utilizing any intravascular approach. One of the motivations for creating a pathway or communication between the aorta and left atrium is to facilitate the study or placement of end-therapy devices. In some examples, the methods of the present disclosure may be used to create a pathway or communication between the aorta and the left atrium to position a stent, a shunt, or a pressure-sensitive catheter in the pathway. The method and system of the present disclosure may also be used to create large perforations between the atria and between the left atrium and aorta, as well as other perforations between other heart chambers and heart regions. All the applications/methods and devices disclosed herein are intended to be exemplary only and are not intended to limit the scope of the present disclosure in any way.
While the above description provides examples of one or more processes or apparatuses or compositions, it will be appreciated that other processes or apparatuses or compositions may be within the scope of the accompanying claims.
To the extent any amendments, characterizations, or other assertions previously made (in this or in any related patent applications or patents, including any parent, sibling, or child) with respect to any art, prior or otherwise, could be construed as a disclaimer of any subject matter supported by the present disclosure of this application, Applicant hereby rescinds and retracts such disclaimer. Applicant also respectfully submits that any prior art previously considered in any related patent applications or patents, including any parent, sibling, or child, may need to be re-visited.
Number | Name | Date | Kind |
---|---|---|---|
175254 | Oberly | Mar 1876 | A |
827626 | Gillet | Jul 1906 | A |
848711 | Weaver | Apr 1907 | A |
1072954 | Junn | Sep 1913 | A |
1279654 | Charlesworth | Sep 1918 | A |
1918094 | Geekas | Jul 1933 | A |
1996986 | Weinberg | Apr 1935 | A |
2021989 | De Master | Nov 1935 | A |
2146636 | Lipchow | Feb 1939 | A |
3429574 | Williams | Feb 1969 | A |
3448739 | Stark et al. | Jun 1969 | A |
3575415 | Fulp et al. | Apr 1971 | A |
3595239 | Petersen | Jul 1971 | A |
4129129 | Amrine | Dec 1978 | A |
4244362 | Anderson | Jan 1981 | A |
4401124 | Guess et al. | Aug 1983 | A |
4639252 | Kelly et al. | Jan 1987 | A |
4641649 | Walinsky et al. | Feb 1987 | A |
4669467 | Willett et al. | Jun 1987 | A |
4682596 | Bales et al. | Jul 1987 | A |
4790311 | Ruiz | Dec 1988 | A |
4790809 | Kuntz | Dec 1988 | A |
4793350 | Mar et al. | Dec 1988 | A |
4807620 | Strul et al. | Feb 1989 | A |
4832048 | Cohen | May 1989 | A |
4840622 | Hardy | Jun 1989 | A |
4863441 | Lindsay et al. | Sep 1989 | A |
4884567 | Elliott et al. | Dec 1989 | A |
4892104 | Ito et al. | Jan 1990 | A |
4896671 | Cunningham et al. | Jan 1990 | A |
4928693 | Goodin et al. | May 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4960410 | Pinchuk | Oct 1990 | A |
4977897 | Hurwitz | Dec 1990 | A |
4998933 | Eggers et al. | Mar 1991 | A |
5006119 | Acker et al. | Apr 1991 | A |
5019076 | Yamanashi et al. | May 1991 | A |
5047026 | Rydell | Sep 1991 | A |
5081997 | Bosley et al. | Jan 1992 | A |
5098392 | Fleischhacker et al. | Mar 1992 | A |
5098431 | Rydell | Mar 1992 | A |
5112048 | Kienle | May 1992 | A |
5154724 | Andrews | Oct 1992 | A |
5190528 | Fonger | Mar 1993 | A |
5201756 | Horzewski et al. | Apr 1993 | A |
5209741 | Spaeth | May 1993 | A |
5211183 | Wilson | May 1993 | A |
5221256 | Mahurkar | Jun 1993 | A |
5230349 | Langberg | Jul 1993 | A |
5281216 | Klicek | Jan 1994 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5300069 | Hunsberger et al. | Apr 1994 | A |
5312341 | Turi | May 1994 | A |
5314418 | Takano et al. | May 1994 | A |
5318525 | West et al. | Jun 1994 | A |
5327905 | Avitall | Jul 1994 | A |
5364393 | Auth et al. | Nov 1994 | A |
5372596 | Klicek et al. | Dec 1994 | A |
5380304 | Parker | Jan 1995 | A |
5395341 | Slater | Mar 1995 | A |
5397304 | Truckai | Mar 1995 | A |
5403338 | Milo | Apr 1995 | A |
5423809 | Klicek | Jun 1995 | A |
5425382 | Golden et al. | Jun 1995 | A |
5490859 | Mische et al. | Feb 1996 | A |
5497774 | Swartz et al. | Mar 1996 | A |
5499975 | Cope et al. | Mar 1996 | A |
5507751 | Goode et al. | Apr 1996 | A |
5509411 | Littmann et al. | Apr 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5545200 | West et al. | Aug 1996 | A |
5555618 | Winkler | Sep 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5575766 | Swartz et al. | Nov 1996 | A |
5575772 | Lennox | Nov 1996 | A |
5599347 | Hart et al. | Feb 1997 | A |
5605162 | Mirzaee et al. | Feb 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5622169 | Golden et al. | Apr 1997 | A |
5624430 | Eton et al. | Apr 1997 | A |
5667488 | Lundquist et al. | Sep 1997 | A |
5673695 | McGee et al. | Oct 1997 | A |
5674208 | Berg et al. | Oct 1997 | A |
5683366 | Eggers et al. | Nov 1997 | A |
5720744 | Eggleston et al. | Feb 1998 | A |
5741249 | Moss et al. | Apr 1998 | A |
5766135 | Terwilliger | Jun 1998 | A |
5779688 | Imran et al. | Jul 1998 | A |
5810764 | Eggers et al. | Sep 1998 | A |
5814028 | Swartz et al. | Sep 1998 | A |
5830214 | Flom et al. | Nov 1998 | A |
5836875 | Webster, Jr. | Nov 1998 | A |
5849011 | Jones et al. | Dec 1998 | A |
5851210 | Torossian | Dec 1998 | A |
5885227 | Finlayson | Mar 1999 | A |
5888201 | Stinson et al. | Mar 1999 | A |
5893848 | Negus et al. | Apr 1999 | A |
5893885 | Webster, Jr. | Apr 1999 | A |
5904679 | Clayman | May 1999 | A |
5916210 | Winston | Jun 1999 | A |
5921957 | Killion et al. | Jul 1999 | A |
5931818 | Werp et al. | Aug 1999 | A |
5944023 | Johnson et al. | Aug 1999 | A |
5951482 | Winston et al. | Sep 1999 | A |
5957842 | Littmann et al. | Sep 1999 | A |
5964757 | Ponzi | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5989276 | Houser et al. | Nov 1999 | A |
6007555 | Devine | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6013072 | Winston et al. | Jan 2000 | A |
6017340 | Cassidy et al. | Jan 2000 | A |
6018676 | Davis et al. | Jan 2000 | A |
6030380 | Auth et al. | Feb 2000 | A |
6032674 | Eggers et al. | Mar 2000 | A |
6036677 | Javier, Jr. et al. | Mar 2000 | A |
6048349 | Winston et al. | Apr 2000 | A |
6053870 | Fulton, III | Apr 2000 | A |
6053904 | Scribner et al. | Apr 2000 | A |
6056747 | Saadat et al. | May 2000 | A |
6063093 | Winston et al. | May 2000 | A |
6093185 | Ellis et al. | Jul 2000 | A |
6106515 | Winston et al. | Aug 2000 | A |
6106520 | Laufer et al. | Aug 2000 | A |
6117131 | Taylor | Sep 2000 | A |
6142992 | Cheng et al. | Nov 2000 | A |
6146380 | Racz et al. | Nov 2000 | A |
6155264 | Ressemann et al. | Dec 2000 | A |
6156031 | Aita et al. | Dec 2000 | A |
6171305 | Sherman | Jan 2001 | B1 |
6179824 | Eggers et al. | Jan 2001 | B1 |
6193676 | Winston et al. | Feb 2001 | B1 |
6193715 | Wrublewski et al. | Feb 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6217575 | Devore et al. | Apr 2001 | B1 |
6221061 | Engelson et al. | Apr 2001 | B1 |
6228076 | Winston et al. | May 2001 | B1 |
6245054 | Fuimaono et al. | Jun 2001 | B1 |
6267758 | Daw et al. | Jul 2001 | B1 |
6270476 | Santoianni | Aug 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6292678 | Hall et al. | Sep 2001 | B1 |
6293945 | Parins et al. | Sep 2001 | B1 |
6296615 | Brockway et al. | Oct 2001 | B1 |
6296636 | Cheng et al. | Oct 2001 | B1 |
6302898 | Edwards et al. | Oct 2001 | B1 |
6304769 | Arenson et al. | Oct 2001 | B1 |
6315777 | Comben | Nov 2001 | B1 |
6328699 | Eigler et al. | Dec 2001 | B1 |
6360128 | Kordis et al. | Mar 2002 | B2 |
6364877 | Goble et al. | Apr 2002 | B1 |
6385472 | Hall et al. | May 2002 | B1 |
6394976 | Winston et al. | May 2002 | B1 |
6395002 | Ellman et al. | May 2002 | B1 |
6419674 | Bowser et al. | Jul 2002 | B1 |
6428551 | Hall et al. | Aug 2002 | B1 |
6450989 | Dubrul et al. | Sep 2002 | B2 |
6475214 | Moaddeb | Nov 2002 | B1 |
6485485 | Winston et al. | Nov 2002 | B1 |
6508754 | Liprie et al. | Jan 2003 | B1 |
6524303 | Garibaldi | Feb 2003 | B1 |
6530923 | Dubrul et al. | Mar 2003 | B1 |
6554827 | Chandrasekaran et al. | Apr 2003 | B2 |
6562031 | Chandrasekaran et al. | May 2003 | B2 |
6562049 | Norlander et al. | May 2003 | B1 |
6565562 | Shah et al. | May 2003 | B1 |
6607529 | Jones et al. | Aug 2003 | B1 |
6632222 | Edwards et al. | Oct 2003 | B1 |
6639999 | Cookingham et al. | Oct 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6651672 | Roth | Nov 2003 | B2 |
6662034 | Segner et al. | Dec 2003 | B2 |
6663621 | Winston et al. | Dec 2003 | B1 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6709444 | Makower | Mar 2004 | B1 |
6723052 | Mills | Apr 2004 | B2 |
6733511 | Hall et al. | May 2004 | B2 |
6740103 | Hall et al. | May 2004 | B2 |
6752800 | Winston et al. | Jun 2004 | B1 |
6755816 | Ritter et al. | Jun 2004 | B2 |
6811544 | Schaer | Nov 2004 | B2 |
6814733 | Schwartz et al. | Nov 2004 | B2 |
6820614 | Bonutti | Nov 2004 | B2 |
6834201 | Gillies et al. | Dec 2004 | B2 |
6842639 | Winston et al. | Jan 2005 | B1 |
6852109 | Winston et al. | Feb 2005 | B2 |
6855143 | Davison et al. | Feb 2005 | B2 |
6860856 | Ward et al. | Mar 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6911026 | Hall et al. | Jun 2005 | B1 |
6951554 | Johansen et al. | Oct 2005 | B2 |
6951555 | Suresh et al. | Oct 2005 | B1 |
6955675 | Jain | Oct 2005 | B2 |
6970732 | Winston et al. | Nov 2005 | B2 |
6980843 | Eng et al. | Dec 2005 | B2 |
7022131 | Derowe | Apr 2006 | B1 |
7029470 | Francischelli et al. | Apr 2006 | B2 |
7048733 | Hartley et al. | May 2006 | B2 |
7056294 | Khairkhahan et al. | Jun 2006 | B2 |
7083566 | Tornes et al. | Aug 2006 | B2 |
7112197 | Hartley et al. | Sep 2006 | B2 |
7335197 | Sage et al. | Feb 2008 | B2 |
7618430 | Scheib | Nov 2009 | B2 |
7651492 | Wham | Jan 2010 | B2 |
7666203 | Chanduszko et al. | Feb 2010 | B2 |
7678081 | Whiting et al. | Mar 2010 | B2 |
7682360 | Guerra | Mar 2010 | B2 |
7828796 | Wong et al. | Nov 2010 | B2 |
7900928 | Held et al. | Mar 2011 | B2 |
8192425 | Mirza et al. | Jun 2012 | B2 |
8257323 | Joseph et al. | Sep 2012 | B2 |
8337518 | Nance et al. | Dec 2012 | B2 |
8388549 | Paul et al. | Mar 2013 | B2 |
8500697 | Kurth et al. | Aug 2013 | B2 |
9072872 | Asleson et al. | Jul 2015 | B2 |
9757541 | Haarer | Sep 2017 | B2 |
11339579 | Stearns | May 2022 | B1 |
20010012934 | Chandrasekaran et al. | Aug 2001 | A1 |
20010021867 | Kordis et al. | Sep 2001 | A1 |
20010044591 | Stevens et al. | Nov 2001 | A1 |
20010051790 | Parker | Dec 2001 | A1 |
20020019644 | Hastings et al. | Feb 2002 | A1 |
20020022781 | McLntire et al. | Feb 2002 | A1 |
20020022836 | Goble et al. | Feb 2002 | A1 |
20020035361 | Houser et al. | Mar 2002 | A1 |
20020087153 | Roschak et al. | Jul 2002 | A1 |
20020087156 | Maguire et al. | Jul 2002 | A1 |
20020111618 | Stewart et al. | Aug 2002 | A1 |
20020123749 | Jain | Sep 2002 | A1 |
20020147485 | Mamo et al. | Oct 2002 | A1 |
20020161424 | Rapacki | Oct 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20020188302 | Berg et al. | Dec 2002 | A1 |
20020198521 | Maguire | Dec 2002 | A1 |
20030032929 | McGuckin | Feb 2003 | A1 |
20030040742 | Underwood et al. | Feb 2003 | A1 |
20030144658 | Schwartz et al. | Jul 2003 | A1 |
20030158480 | Tornes et al. | Aug 2003 | A1 |
20030163153 | Scheib | Aug 2003 | A1 |
20030208220 | Worley et al. | Nov 2003 | A1 |
20030225392 | McMichael et al. | Dec 2003 | A1 |
20040015162 | McGaffigan | Jan 2004 | A1 |
20040024396 | Eggers | Feb 2004 | A1 |
20040030328 | Eggers et al. | Feb 2004 | A1 |
20040044350 | Martin et al. | Mar 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20040077948 | Violante et al. | Apr 2004 | A1 |
20040116851 | Johansen et al. | Jun 2004 | A1 |
20040127963 | Uchida et al. | Jul 2004 | A1 |
20040133113 | Krishnan | Jul 2004 | A1 |
20040133130 | Ferry et al. | Jul 2004 | A1 |
20040143256 | Bednarek | Jul 2004 | A1 |
20040147950 | Mueller et al. | Jul 2004 | A1 |
20040181213 | Gondo | Sep 2004 | A1 |
20040230188 | Cioanta et al. | Nov 2004 | A1 |
20050004585 | Hall et al. | Jan 2005 | A1 |
20050010208 | Winston et al. | Jan 2005 | A1 |
20050049628 | Schweikert et al. | Mar 2005 | A1 |
20050059966 | McClurken et al. | Mar 2005 | A1 |
20050065507 | Hartley et al. | Mar 2005 | A1 |
20050085806 | Auge et al. | Apr 2005 | A1 |
20050096529 | Cooper et al. | May 2005 | A1 |
20050119556 | Gillies et al. | Jun 2005 | A1 |
20050137527 | Kunin | Jun 2005 | A1 |
20050149012 | Penny et al. | Jul 2005 | A1 |
20050203504 | Wham et al. | Sep 2005 | A1 |
20050203507 | Truckai et al. | Sep 2005 | A1 |
20050261607 | Johansen et al. | Nov 2005 | A1 |
20050288631 | Lewis et al. | Dec 2005 | A1 |
20060041253 | Newton et al. | Feb 2006 | A1 |
20060074398 | Whiting et al. | Apr 2006 | A1 |
20060079769 | Whiting et al. | Apr 2006 | A1 |
20060079787 | Whiting et al. | Apr 2006 | A1 |
20060079884 | Manzo et al. | Apr 2006 | A1 |
20060085054 | Zikorus et al. | Apr 2006 | A1 |
20060089638 | Carmel et al. | Apr 2006 | A1 |
20060106375 | Werneth et al. | May 2006 | A1 |
20060135962 | Kick et al. | Jun 2006 | A1 |
20060142756 | Davies et al. | Jun 2006 | A1 |
20060189972 | Grossman | Aug 2006 | A1 |
20060241586 | Wilk | Oct 2006 | A1 |
20060247672 | Vidlund et al. | Nov 2006 | A1 |
20060264927 | Ryan | Nov 2006 | A1 |
20060276710 | Krishnan | Dec 2006 | A1 |
20070060879 | Weitzner et al. | Mar 2007 | A1 |
20070066975 | Wong et al. | Mar 2007 | A1 |
20070118099 | Trout, III | May 2007 | A1 |
20070123964 | Davies et al. | May 2007 | A1 |
20070167775 | Kochavi et al. | Jul 2007 | A1 |
20070185522 | Davies et al. | Aug 2007 | A1 |
20070208256 | Marilla | Sep 2007 | A1 |
20070225681 | House | Sep 2007 | A1 |
20070270791 | Wang et al. | Nov 2007 | A1 |
20080039865 | Shaher et al. | Feb 2008 | A1 |
20080042360 | Veikley | Feb 2008 | A1 |
20080086120 | Mirza et al. | Apr 2008 | A1 |
20080097213 | Carlson et al. | Apr 2008 | A1 |
20080108987 | Bruszewski et al. | May 2008 | A1 |
20080146918 | Magnin et al. | Jun 2008 | A1 |
20080171934 | Greenan et al. | Jul 2008 | A1 |
20080208121 | Youssef et al. | Aug 2008 | A1 |
20080243081 | Nance et al. | Oct 2008 | A1 |
20080243222 | Schafersman et al. | Oct 2008 | A1 |
20080275439 | Francischelli et al. | Nov 2008 | A1 |
20090105742 | Kurth et al. | Apr 2009 | A1 |
20090138009 | Viswanathan et al. | May 2009 | A1 |
20090163850 | Betts et al. | Jun 2009 | A1 |
20090177114 | Chin et al. | Jul 2009 | A1 |
20090264977 | Bruszewski et al. | Oct 2009 | A1 |
20100022948 | Wilson et al. | Jan 2010 | A1 |
20100087789 | Leeflang et al. | Apr 2010 | A1 |
20100125282 | Machek et al. | May 2010 | A1 |
20100168684 | Ryan | Jul 2010 | A1 |
20100179632 | Bruszewski et al. | Jul 2010 | A1 |
20100191142 | Paul et al. | Jul 2010 | A1 |
20100194047 | Sauerwine | Aug 2010 | A1 |
20100249908 | Chau et al. | Nov 2010 | A1 |
20110046619 | Ducharme | Feb 2011 | A1 |
20110087261 | Wittkampf | Apr 2011 | A1 |
20110130619 | Whisenant | Jun 2011 | A1 |
20110130752 | Ollivier | Jun 2011 | A1 |
20110152716 | Chudzik et al. | Jun 2011 | A1 |
20110160592 | Mitchell | Jun 2011 | A1 |
20110190763 | Urban et al. | Aug 2011 | A1 |
20120109079 | Asleson | May 2012 | A1 |
20120232546 | Mirza et al. | Sep 2012 | A1 |
20120265055 | Melsheimer et al. | Oct 2012 | A1 |
20120330156 | Brown et al. | Dec 2012 | A1 |
20130184551 | Paganelli et al. | Jul 2013 | A1 |
20130184735 | Fischell et al. | Jul 2013 | A1 |
20130282084 | Mathur et al. | Oct 2013 | A1 |
20140206987 | Urbanski et al. | Jul 2014 | A1 |
20140296769 | Hyde et al. | Oct 2014 | A1 |
20150157353 | Lenker et al. | Jun 2015 | A1 |
20160175009 | Davies | Jun 2016 | A1 |
20160220741 | Garrison et al. | Aug 2016 | A1 |
20190021763 | Zhou et al. | Jan 2019 | A1 |
20190247035 | Gittard et al. | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
2550988 | Jan 2013 | EP |
3064246 | Sep 2016 | EP |
2002532164 | Oct 2002 | JP |
2007510458 | Apr 2007 | JP |
2009537255 | Oct 2009 | JP |
2010227580 | Oct 2010 | JP |
2011206179 | Oct 2011 | JP |
2015504328 | Feb 2015 | JP |
2016530928 | Oct 2016 | JP |
2005065562 | Jul 2005 | WO |
2008066557 | Jun 2008 | WO |
2008079828 | Jul 2008 | WO |
2011014496 | Feb 2011 | WO |
2013101632 | Jul 2013 | WO |
2014182969 | Nov 2014 | WO |
Number | Date | Country | |
---|---|---|---|
20210259732 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
62981434 | Feb 2020 | US |